REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 155 filers reported holding REVANCE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $261,447 | -56.5% | 22,794 | -4.1% | 0.00% | – |
| Q2 2023 | $601,669 | -16.6% | 23,772 | +6.2% | 0.00% | -100.0% |
| Q1 2023 | $721,053 | +178.5% | 22,386 | +59.6% | 0.00% | – |
| Q4 2022 | $258,865 | -64.9% | 14,023 | -48.7% | 0.00% | -100.0% |
| Q3 2022 | $738,000 | +301.1% | 27,344 | +104.9% | 0.00% | – |
| Q2 2022 | $184,000 | -8.0% | 13,343 | +30.1% | 0.00% | – |
| Q1 2022 | $200,000 | -62.9% | 10,253 | -47.0% | 0.00% | -100.0% |
| Q3 2021 | $539,000 | -30.5% | 19,347 | -26.0% | 0.00% | 0.0% |
| Q2 2021 | $775,000 | -5.9% | 26,152 | -11.3% | 0.00% | 0.0% |
| Q1 2021 | $824,000 | -6.2% | 29,494 | -4.8% | 0.00% | 0.0% |
| Q4 2020 | $878,000 | -14.6% | 30,991 | -24.2% | 0.00% | -50.0% |
| Q3 2020 | $1,028,000 | +6.1% | 40,884 | +3.0% | 0.00% | 0.0% |
| Q2 2020 | $969,000 | – | 39,694 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Essex Woodlands Management, Inc. | 3,342,047 | $94,714,000 | 24.58% |
| Palo Alto Investors LP | 2,673,313 | $75,762,000 | 3.97% |
| Evolutionary Tree Capital Management, LLC | 89,348 | $2,532,000 | 1.93% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,121,152 | $31,773,000 | 1.12% |
| ArrowMark Colorado Holdings LLC | 2,964,135 | $84,004,000 | 0.65% |
| Rhenman & Partners Asset Management AB | 220,000 | $6,235,000 | 0.51% |
| Fosun International Ltd | 233,841 | $6,627,000 | 0.43% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 174,970 | $4,959,000 | 0.30% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 76,671 | $2,173,000 | 0.27% |
| Tekla Capital Management LLC | 213,808 | $6,059,000 | 0.21% |